SF3B1 mutations occurring in MDS result in different splicing alterations that define a disease characterized by RS, ineffective erythropoiesis and low risk of conversion to leukemia, and high overall survival (OS) (5), together suggesting a mechanism of action in MDS. This evidence concerns the gene SF3B1 and leukemia.